Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-8E12 in Early Alzheimer's Disease
2016-001634-10Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ABBV-8E12 with Placebo (2 arms). Primary endpoint: CDR-SB. Started Nov 2016; status: completed.
02
Drugs
tilavonemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-001634-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001634-10.